Heart failure & cardiomyopathiesCohort study
Real-World Experience With Mavacamten in SRT-Eligible Obstructive HCM
- retrospective review
- single institution
- real-world
Authors' conclusion
In SRT-eligible oHCM, mavacamten use was associated with sustained hemodynamic and symptomatic improvement and was generally well tolerated in this real-world cohort. Institutional SRT volumes also declined during the post-mavacamten era.
Study context
- Population
- Patients with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten who met guideline-based septal reduction therapy (SRT) eligibility criteria, April 2022 to December 2025SRT-eligible, of 84 patients treated with mavacamten
- Participants
- 53 patients
- Exposure
- Baseline vs follow-up; institutional SRT volumes before vs after mavacamten approval
- Mavacamtenn = 53
Main finding
As reported in the abstract
Baseline
51 ± 39 mm Hg
Follow-up
4 ± 7 mm Hg
Observational data: associations, not effects.
Further findings
LVOT gradient with Valsalva · median follow-up of 82 weeks
- Baseline
- 79 ± 35 mm Hg
- Follow-up
- 9 ± 15 mm Hg
- P < 0.001
Improvement by ≥1 NYHA functional class
- Patients improved
- 49 patients (92%)
SRT eligibility / SRT undergone · most recent follow-up
- No patients remained guideline-eligible for SRT or elected to undergo SRT
Institutional SRT volume
- Declined significantly after mavacamten approval
Baseline characteristics
- Mean age
- 67 ± 13 years
- Females
- 72%
Safety
Transient LVEF reduction to <50%
- Patients
- 6 patients (11%)
New or recurrent atrial fibrillation
- Patients
- 7 (13%)
Original publication
Summarised from the published abstract; every number is checked against it